Tradestie Institutional Equity Comparison Engine

BMY vs NVS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BMY Overall Edge

BMY Captures Institutional Edge (4โ€“0 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Bristol-Myers Squibb Co. (BMY) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BMY trades at 9.5x Forward P/E with 32.4% operating margin (+6.9% YoY revenue) versus NVS at 16.2x Forward P/E and 34.0% operating margin (+4.7% YoY). In options structure, BMY sits in CONSOLIDATION (56th %ile IV; Dealer Gamma Walls on Pro) against NVS sits in UNCLASSIFIED (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner BMY
BMY 9.5x vs NVS 16.2x Fwd P/E
Growth & Margin Winner BMY
Op Margin 32.4% vs 34.0% ยท YoY +6.9% vs +4.7%
Momentum & Technical Winner BMY
1Y +30.2% vs +22.5% ยท 52W Pos 77% vs 81%
Options & Structure Winner BMY
CONSOLIDATION (56th %ile IV) vs UNCLASSIFIED (6th %ile IV)
BMY NYSE
Bristol-Myers Squibb Co.
Pharmaceutical Preparations
$63.30
-0.21% 1D
Market Cap $127.4B
1M Return +5.93%
1Y Return +30.16%
Forward P/E 9.5x
Unified AI Score
57.3 / 100 HOLD
Tech 62.0 Fund 61.0 Flow 70.0 Mom 50.0
NVS NYSE
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap $302.9B
1M Return +7.28%
1Y Return +22.5%
Forward P/E 16.2x
Unified AI Score
41.5 / 100 SELL
Tech 29.0 Fund 38.0 Flow 50.0 Mom 21.1

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BMY +30.16% NVS +22.5% Spread: +7.66 pp (BMY Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BMY TTM Op. Margin: 32.4% NVS TTM Op. Margin: 34.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BMY vs NVS. Trailing 12-month operating profitability (BMY 32.4% vs NVS 34.0%) and valuation multiples (BMY 9.5x vs NVS 16.2x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BMY (6) vs NVS (4)
Institutional Metric BMY NVS Criterion Row Winner
Market Capitalization Scale $127.4B $302.9B Larger Scale NVS
Trailing P/E Ratio Valuation 13.8x 30.6x Lower Multiple BMY
Forward P/E Ratio Valuation 9.5x 16.2x Lower Multiple BMY
Revenue Growth (YoY) Growth +6.9% +4.7% Higher Growth BMY
Operating Margin (TTM) Profitability 32.4% 34.0% Higher Margin NVS
Net Profit Margin Profitability 18.5% 17.5% Higher Margin BMY
Return on Equity (ROE) Capital Efficiency 44.0% 24.3% Higher ROE BMY
52-Week Range Position Momentum 77% ($45โ€“$69) 81% ($123โ€“$170) Stronger Trend NVS
Beta / 30D Volatility Risk Regime 0.17ฮฒ ยท 31% Vol 0.31ฮฒ ยท 27% Vol Lower Realized Risk NVS
Unified Institutional Score Composite Signal 57.3 / 100 (HOLD) 41.5 / 100 (SELL) Higher Composite BMY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BMY vs NVS Buy Guide
BMY CONSOLIDATION
50d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 56th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live BMY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NVS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live NVS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BMY nor NVS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.